(NewsNation) — Drugmaker MannKind announced that its inhaled insulin, Afrezza, has been approved for an application to help treat diabetes in children.

According to a news release from the company, Afrezza is a fast-acting insulin that is delivered through an inhaler. When used, the inhaler releases a powder into the lungs.

The acceptance comes after a study done by the American Diabetes Association in June found that inhaled insulin is safe and effective for children.

"Today’s milestone brings us one step closer to offering young children and teenagers living with diabetes a potential alternative therapy to multiple daily injections or an insulin pump system," Dr. Kevin Kaiserman of MannKind said.

Afrezza first received FDA approval for adults 18 and older in June 2014.

If approved,

See Full Page